Adverum Biotechnologies Inc [NASDAQ: ADVM] gained 17.34% on the last trading session, reaching $4.06 price per share at the time.
Adverum Biotechnologies Inc represents 20.98 million in outstanding shares, while the company has a total market value of $85.20 million with the latest information. ADVM stock price has been found in the range of $3.5401 to $5.19.
If compared to the average trading volume of 176.37K shares, ADVM reached a trading volume of 8656301 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adverum Biotechnologies Inc [ADVM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADVM shares is $19.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADVM stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Adverum Biotechnologies Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 25, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on April 30, 2024, representing the official price target for Adverum Biotechnologies Inc stock. Previously, the target price had yet another raise to $4, while Truist analysts kept a Buy rating on ADVM stock.
Trading performance analysis for ADVM stock
Adverum Biotechnologies Inc [ADVM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 34.44. With this latest performance, ADVM shares gained by 36.70% in over the last four-week period, additionally sinking by -24.81% over the last 6 months – not to mention a drop of -13.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADVM stock in for the last two-week period is set at 67.75, with the RSI for the last a single of trading hit 0.55, and the three-weeks RSI is set at 0.38 for Adverum Biotechnologies Inc [ADVM]. The present Moving Average for the last 50 days of trading for this stock 2.89, while it was recorded at 3.42 for the last single week of trading, and 3.55 for the last 200 days.
Adverum Biotechnologies Inc [ADVM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Adverum Biotechnologies Inc [ADVM] shares currently have an operating margin of -17441.50% and a Gross Margin at -191.80%. Adverum Biotechnologies Inc’s Net Margin is presently recorded at -16427.50%.
Adverum Biotechnologies Inc (ADVM) Capital Structure & Debt Analysis
According to recent financial data for Adverum Biotechnologies Inc. ( ADVM), the Return on Equity (ROE) stands at -222.28%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -93.88%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Adverum Biotechnologies Inc’s Return on Invested Capital (ROIC) is -254.14%, showcasing its effectiveness in deploying capital for earnings.
Adverum Biotechnologies Inc (ADVM) Efficiency & Liquidity Metrics
Adverum Biotechnologies Inc (ADVM) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Adverum Biotechnologies Inc. (ADVM) effectively leverages its workforce, generating an average of -$1059870.97 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.54% and a Quick Ratio of 1.54%, indicating strong ability to cover short-term liabilities.
Adverum Biotechnologies Inc [ADVM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adverum Biotechnologies Inc posted -1.3/share EPS, while the average EPS was predicted by analysts to be reported at -1.3/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADVM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adverum Biotechnologies Inc go to 36.36%.
An analysis of Institutional ownership at Adverum Biotechnologies Inc [ADVM]
There are presently around $67.45%, or 77.57%% of ADVM stock, in the hands of institutional investors. The top three institutional holders of ADVM stocks are: TCG CROSSOVER MANAGEMENT, LLC with ownership of 2.01 million shares, which is approximately 12.1873%. BML CAPITAL MANAGEMENT, LLC, holding 1.97 million shares of the stock with an approximate value of $$13.49 million in ADVM stocks shares; and BML CAPITAL MANAGEMENT, LLC, currently with $$12.07 million in ADVM stock with ownership which is approximately 8.4407%.
